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aspirin and a P2Y12 inhibitor) might thus be indicated; how-
ever, this may lead to an unacceptably high bleeding risk. To 
complicate clinical decision making further, the non-vitamin 
K antagonist oral anticoagulants (NOACs) have been intro-
duced as an alternative to vitamin K antagonists (VKA) and 
are recommended in many patients because of their favour-
able risk profile and adequate stroke prevention [3, 4].
In this article, we will summarise the practical advice on 
the management of ACS patients requiring OAC, following 
the recent consensus document of the European Society of 
Cardiology (ESC) Working Group on Thrombosis in associ-
ation with the European Heart Rhythm Association (EHRA)
[5] and the ESC guidelines on ACS and atrial fibrillation 
[6–8].
Antithrombotic management of a patient on an OAC 
in the cath lab
The majority of the patients presenting with ACS have an 
indication for coronary angiography (CAG). While the 
most commonly used anticoagulant, unfractionated heparin, 
reduces the risk of ischaemic complications during CAG 
and percutaneous coronary intervention (PCI), such as 
catheter thrombosis and stent thrombosis, it also increases 
the risk of bleeding [9]. When a patient is already on an 
OAC when going to the catheterisation laboratory (cath 
lab) we have to decide on: (1) whether to continue the OAC 
throughout CAG and PCI; (2) if the OAC treatment is inter-
rupted, whether heparin bridging is needed and (3) which 
access site is optimal.
Abstract A significant number of patients with atrial fi-
brillation, treated with oral anticoagulants, present with an 
acute coronary syndrome. Many of these patients have an 
indication for coronary angiography. The introduction of 
non-vitamin K antagonist oral anticoagulants (NOACs) 
and the novel P2Y12 inhibitors has generated new uncer-
tainty about the optimal treatment regimen, whether triple 
or dual therapy should be given and which is the most 
beneficial P2Y12 inhibitor (clopidogrel, ticagrelor, prasug-
rel). In this article, we will summarise the practical advice 
on the management of acute coronary syndrome patients 
requiring oral anticoagulants following the recent con-
sensus document of the European Society of Cardiology 
(ESC) Working Group on Thrombosis in association with 
the European Heart Rhythm Association (EHRA) and ESC 
guidelines.
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Introduction
Around 5–10 % of the patients presenting with an acute 
coronary syndrome (ACS) have atrial fibrillation (AF) and 
use oral anticoagulants (OAC) [1, 2]. In addition to OAC, 
these patients have an indication for dual antiplatelet ther-
apy (DAPT), comprising a P2Y12 inhibitor (clopidogrel, 
prasugrel, ticagrelor) and aspirin. Triple therapy (OAC plus 
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Heparin bridging versus uninterrupted VKA
The AFCAS (prospective multicenter Atrial Fibrillation 
undergoing Coronary Artery Stenting) registry has shown 
that an uninterrupted approach with VKA was equally safe 
as bridging therapy during PCI while also being simpler 
and cost-effective [10]. Furthermore, addition of heparin 
to uninterrupted VKA during the procedure resulted in an 
increase of minor bleeding and access site complications 
(11.2 versus 5.5 %, p = 0.03) while not reducing thrombotic 
event rates. Also the recent substudy from the WOEST 
(What is the Optimal antiplatelet and anticoagulant therapy 
in patients with oral anticoagulation and coronary StenT-
ing) trial has shown fewer early bleeding events following 
PCI in the uninterrupted VKA group and no difference in 
thrombotic events as compared with the patients undergoing 
bridging [11]. Although not based on randomised data, the 
ESC consensus document recommends the uninterrupted 
approach without bridging in patients on VKA [5].
What to do if the patient is on an NOAC?
There are no randomised data whether to discontinue NOACs 
or proceed with CAG on treatment. The ESC consensus 
document states that for interventions with no clinically 
important bleeding risk, the procedure can be performed 
while the patient is being treated with an NOAC, as long 
as there is no peak concentration of the drug (thus 12–24 h 
after intake) [5]. For a minimal bleeding risk intervention, 
such as CAG, it is recommended to stop the NOAC 24 h 
before the procedure. In patients undergoing a procedure 
with a high bleeding risk (e.g. CABG) it is recommended to 
stop NOACs at least 48 h before the procedure. In patients 
treated with NOACs, bridging is usually not necessary, due 
to the fast-onset and offset action of these agents.
When there is no time to discontinue an NOAC, one 
has to remember that it provides insufficient anticoagula-
tion during catheter intervention. An in vivo study by Yau 
et al. found that NOACs do not prevent contact activation 
such as occurs in a catheter [12]. A small randomised PCI 
trial by Vranckx et al., comparing pre-procedural dabigatran 
with standard procedural unfractionated heparin, also sug-
gests that dabigatran does not provide sufficient anticoagu-
lation as there was more need for bail-out anticoagulants 
and more periprocedural infarctions occurred in the dabi-
gatran group [13]. The Dresden NOAC registry in patients 
undergoing PCI has shown that NOAC interruption without 
heparin bridging did not increase thrombotic event rates, 
while major bleeding complications were more common 
with heparin bridging [14]. Whether NOAC continuation 
and adding low-dose unfractionated heparin during CAG is 
a better option than NOAC discontinuation before CAG has 
to be proven before it can be recommended.
The use of fondaparinux in the cath lab is not an option 
because it also does not prevent catheter thrombosis in 
patients with ACS undergoing PCI as was shown by the 
OASIS trials, comparing fondaparinux with enoxaparin in 
patients presenting with non-ST-elevation ACS (OASIS V) 
[15] and ST-elevation myocardial infarction (OASIS VI) 
[16].
Multiple trials have shown that bivalirudin is an alter-
native to periprocedural heparin in ACS patients [17, 18]. 
The major advantage of bivalirudin is the reduced risk of 
bleeding as compared with heparin plus glycoprotein IIb/
IIIa inhibitor (GPI). The ACUITY-PCI trial has shown that 
bivalirudin alone can safely replace heparin and GPI in ACS 
patients undergoing PCI with less major bleeding and with 
no differences in net clinical outcomes [19]. The BRIGHT 
trial, of which the preliminary results were presented during 
the Transcatheter Cardiovascular Therapeutics (TCT) 2014, 
confirms these findings. A reduction of 50–60 % in bleeding 
events in the bivalirudin-treated patients versus the heparin 
monotherapy or heparin+GPI groups (p = 0.041 and 0.001, 
respectively) was seen. However, the HEAT-PPCI trial has 
shown no difference in bleeding events but an increase in 
stent thrombosis with bivalirudin, compared with heparin, 
when bailout GPI were used in both arms [20].
In summary: according to the ESC consensus document 
NOACs should be stopped 24 h before CAG and UFH bolus 
(a dosage of 60 IU/kg may be considered) or bivalirudin 
(high bleeding risk) should be used during the procedure [5]. 
When there is no time to discontinue the NOAC (ongoing 
ischaemia) additional heparin or bivalirudin should be used.
Choice of approach
The radial approach is preferred to the femoral approach as 
it leads to less bleeding and vascular complications [21]. 
In the RIVAL (Radial versus Femoral Access for Coronary 
Intervention) trial (n = 7021), the primary composite end-
point, death, MI, stroke or bleeding at 30 days, did not differ 
between the femoral and radial access sites; however major 
vascular complications were lower in the radial group (1.4 
vs. 3.7 %, p < 0.0001), which was primarily due to fewer 
haematomas [22]. In a study by Baker et al. (n = 255) in 
patients on OAC undergoing PCI, the radial approach was 
associated with a decrease in any vascular or bleeding com-
plication compared with the femoral approach (1.6 vs 8.1 %, 
p = 0.02) [23].
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endpoints, while the risk of bleeding was reduced with a 
shorter DAPT duration. [26–29] In contrast, the large 
DAPT Study has shown that DAPT for 30 months versus 
12 months after DES reduced the risk of stent thrombosis 
and major adverse cardiac and coronary events (MACCE). 
While bleeding was more common in subjects continuing 
DAPT treatment, major or fatal bleeding were uncommon 
and not statistically significant [30]. In summary, the above 
trials suggest that especially in patients requiring a combi-
nation of OAC+P2Y12 inhibitor after second-generation 
DES implantation, a shorter treatment duration could be 
considered beneficial due to less risk of bleeding events.
Is triple therapy needed in all these patients?
On theoretical grounds, triple therapy (OAC+aspirin+P2Y12 
inhibitor) seems to be the most effective treatment in the 
prevention of thrombotic events in patients with AF present-
ing with ACS; this applies to both conservatively treated 
patients and those undergoing PCI with stent implantation. 
However, large prospective studies have shown that triple 
therapy is associated with a significant (frequently unaccept-
able) increase (2–44x) in major bleeding. ([31–33; Table 1.)
The randomised WOEST trial demonstrated that dual 
therapy significantly reduced bleeding events and MACCE 
in patients with AF undergoing PCI, when compared with 
triple therapy [34]. The study was, however, small and not 
powered to show a difference in thrombotic events such as 
stent thrombosis. Nevertheless, support for the results from 
the WOEST trial comes from multiple large registries [31–
33]. In a nationwide Danish registry of antithrombotic use 
in AF patients discharged after myocardial infarction and 
PCI (n = 11,480), dual therapy (OAC+clopidogrel) reduced 
bleeding events (HR 0.78; CI 0.55–1.12) and thrombotic 
events (HR 0.69; CI 0.48–1.00) when compared with triple 
therapy [32]. An analysis of the AFCAS registry has shown 
that one-year efficacy and safety of all strategies (triple 
therapy, DAPT and dual therapy) in patients with AF under-
going coronary artery stenting were comparable after pro-
pensity matching, suggesting that dual therapy is as safe as 
triple therapy in regard to thrombotic risk [33].
Can noacs be combined with antiplatelet therapy?
The evidence concerning the combination of NOACs and 
antiplatelet therapy is scarce. However, since most phase III 
clinical trials in patients with AF demonstrated that NOACs, 
in general, reduced bleeding events without compromising 
efficacy, they might be a better alternative than VKA in 
these patients presenting with ACS. This may especially be 
the case when a patient has a low time-in-therapeutic-range 
on VKA. However, even low-dose (2.5–5 mg) rivaroxaban 
(lower than the therapeutic dose [20 mg] for AF), added to 
Summary
The uninterrupted OAC without bridging approach is recommended 
in ACS patients on VKA [10, 11] (Level of Evidence: B)
It is recommended to stop NOACs in all patients 24 h before 
coronary angiography, bridging is usually not needed [3, 5] (Level 
of Evidence: C)
Standalone NOAC provides insufficient anticoagulation during 
catheterisation and therefore either heparin or bivalirudin (in ACS 
patients) should be used [9, 10] (Level of Evidence: C)
When a parenteral anticoagulant is needed to support PCI in a pa-
tient at high risk of bleeding, bivalirudin should be considered as an 
alternative to unfractionated heparin [17, 18] a(Level of Evidence: 
A)
Radial access is the default choice for coronary angiography/inter-
vention to minimise the risk of access site-related bleeding depend-
ing on the operator in all patients [15, 17] (Level of Evidence: A)
New-generation DES (or BMS) are preferred over first-generation 
DES (Level of Evidence: C)
aIncreased risk of stent thrombosis, the HEAT-PPCI trial did not 
show a significant difference between bivalirudin and heparin, Note: 
Levels of evidence following the European Society of Hypertension 
(EHS)/ESC guidelines classification scheme.
Level of Evidence A: Data derived from multiple randomised clinical 
trials or meta-analyses.
Level of Evidence B: Data derived from a single randomised trial, or 
nonrandomised studies.
Level of Evidence C: Only consensus opinion of experts, case studies, 
or standard-of-care.
Antithrombotic management of the first year after PCI
Most thromboembolic events in AF are due to systemic 
embolism of thrombus from the left atrial appendage. The 
pathophysiological mechanism for thromboembolic events 
is fibrin mediated, whereas the most important underlying 
pathophysiological mechanism in ACS is platelet aggrega-
tion with secondary activation of the coagulation cascade 
[24]. In line with the pathophysiological mechanisms, the 
ACTIVE W trial has shown that VKA is the superior treat-
ment for AF patients as compared with DAPT, while for 
patients undergoing stenting, DAPT was superior to the 
combination of warfarin and aspirin in the prevention of 
stent thrombosis [25]. AF patients with an indication for 
OAC should therefore continue to use OAC in combination 
with one or more antiplatelet agents when presenting with 
ACS. The goal is to maintain a reduced INR of 2.0–2.5 dur-
ing combination of VKA and antiplatelet therapy.
First-generation drug-eluting stents (DES) require a 
longer period of DAPT than bare-metal stents (BMS) to 
prevent stent thrombosis, since observational studies have 
shown an increase in the occurrence of late and very late 
stent thrombosis. The second-generation DES have theoret-
ical advantages over the first generation, such as a thin-strut 
design, reduced polymer layer, as well as novel anti-prolific 
drugs. Recent evidence from multiple clinical trials testing a 
short duration (3–6 months) versus 12–24 months of DAPT 
therapy has shown no significant difference in thrombotic 
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New-generation P2Y12 inhibitors
While the newer generation of platelet inhibitors (ticagre-
lor or prasugrel) have been introduced to provide stronger 
platelet inhibition and have shown to be more effective in 
reducing death, MI and stroke as compared with clopido-
grel, they have a higher bleeding risk [37, 38]. Data on the 
use of new-generation P2Y12 inhibitor in the context of dual 
or triple therapy is still limited. A recent small observational 
study (n = 355) by Sarafoff et al. has shown that prasugrel as 
part of triple therapy in patients on VKA increased throm-
bolysis in myocardial infarction (TIMI) minor and major 
bleeding events (28.6 versus 6.7 %; adjusted HR 3.2, 95 % 
CI 1.1–9.1), while not significantly reducing thrombotic 
adverse [31]. Another small (n = 255) observational study 
by Braun, comparing patients on dual therapy with ticagre-
lor versus a historical control cohort discharged with triple 
therapy, thrombotic and bleeding events were similar [39].
Until more evidence becomes available, the use of 
ticagrelor or prasugrel in the context of double or triple 
therapy is not recommended as stated in the ESC consen-
sus document. The PIONEER-AF and RE-DUAL trials will 
evaluate the safety of two different rivaroxaban and dabi-
gatran treatment strategies as compared with VKA utilising 
various combinations of antiplatelet therapy using clopi-
dogrel or prasugrel/ticagrelor in patients with non-valvular 
AF who undergo PCI with stent placement (NCT01830543, 
NCT02164864).
DAPT in patients presenting with ACS, was associated with 
an increased risk of major bleeding including intracranial 
haemorrhage in the randomised ATLAS ACS 2– TIMI 51 
trial [35]. As the occurrence of especially myocardial infarc-
tion was reduced by adding rivaroxaban, this trial lends sup-
port that NOACs may reduce ischaemic events after ACS.
A meta-analysis by Oldgren et al. [36] of all phase II 
and III NOAC trials investigating the combination of an 
NOAC with single (aspirin) or dual (aspirin and clopido-
grel) antiplatelet therapy in the ACS setting has shown a 
modest reduction in cardiovascular events with a substan-
tial increase in bleeding, most pronounced in patients using 
DAPT. To make this issue even more complicated: in the 
above trials, clopidogrel was used while the standard of care 
in ACS nowadays includes the more potent novel P2Y12 
inhibitors (ticagrelor or prasugrel).
In patients already using an NOAC before PCI, the ESC 
consensus document recommends to continue the use of the 
NOAC and combine it with antiplatelet therapy. In addition, 
it is advised that when NOACs are used in dual or triple ther-
apy, to consider the use of the lower dose tested for stroke 
prevention in AF (dabigatran 110 mg twice daily, rivaroxa-
ban 15 mg once daily or apixaban 2.5 mg twice daily) [5].
The advised duration of triple therapy in ACS patients 
ranges from 4 weeks for patients with a high bleeding risk 
(HAS-BLED ≥ 3) to 6 months for patients with a low to 
moderate bleeding risk (HAS-BLED 0–2), followed by dual 
therapy (clopidogrel 75 mg/day (or alternatively, aspirin 
75–100 mg/day).
Table 1 Triple therapy versus dual therapy (OAC+aspirin or P2Y12 inhibitor)
Sarafoff et al. (regis-
try) [31]
Lamberts et al. (registry) 
[32]
AFCAS (registry) [33] WOEST (Multicentre, RCT) 
[34]
Population Indication OAC+DES AF+ACS and/or PCI with 
stenting
AF+PCI with stenting OAC indication+PCI with 
stenting
No. of patients 515 (209 DAPT, 306
TT)
11480 (Danish national 
registry)
975 (914 included in final 
analysis)
563
Follow-up in months 24 12 12 12
Therapy Triple vs double 
therapy
TT vs vitamin K 
antagonist+aspirin or 
clopidogrel
TT vs double therapy 
(OAC+clopidogrel)
TT vs dual therapy
Ischaemic endpoint Death, MI, ST or 
stroke




Death, myocardial infarction, 
stroke, target-vessel revascu-
larisation, and stent thrombosis
Event rate, % 14.1 vs 18.0 14.2 vs 9.7 22.0 vs 18 17.6 vs 11.1
Hazard ratio (95 % CI) 0.76 (0.48–1.21) HR 1.15; 95 % CI 0.95–1.40 NR (93.9 vs 94.5 % event free) 0.60 (0.38–0.94])
P-value 0.25 - 0.72 0.027
Bleeding endpoint TIMI major Hospitalisation for fatal or 
nonfatal bleeding
BARC major bleeding TIMI major
Event rate, % 1.4 vs 3.1 14.2 vs 9.7 10 vs 7 5.6 vs 3.2
Hazard ratio (95 % CI) NR HR 1.41 (1.10–1.81) NR (93.7 vs 95.8 event free) 0.56 (0.25–1.27)
P-value NR NR 0.43 0.159
ACS acute coronary syndrome, AF atrial fibrillation, BARC Bleeding Academic Research Consortium, CI confidence interval, DAPT dual 
antiplatelet therapy, HR hazard ratio, MI myocardial infarction, NR not reported, OAC oral anticoagulants, PCI percutaneous coronary 
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